- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.08. | Tenaya Therapeutics auf Konferenz von Canaccord Genuity: Wichtige Katalysatoren für Q4 stehen bevor | 3 | Investing.com Deutsch | ||
| 15.07. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | 8 | GlobeNewswire (USA) | ||
| 06.07. | Piper Sandler bestätigt Tenaya mit "Overweight" und Kursziel von 40 $ | 23 | Investing.com Deutsch | ||
| 06.07. | Piper Sandler reiterates Overweight on Tenaya stock, $40 target | 5 | Investing.com | ||
| TENAYA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 29.06. | Tenaya Therapeutics, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 29.06. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer | 382 | GlobeNewswire (Europe) | SOUTH SAN FRANCISCO, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen | |
| 26.06. | Tenaya Group, Inc. - REVOKED, Commission order revoking Exchange Act registration [Section 12(j)] | 4 | SEC Filings | ||
| 03.06. | Tenaya reports interim data from gene therapy trial for rare heart condition | 5 | Investing.com | ||
| 03.06. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Interim Data from MyPEAK-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms | 13 | GlobeNewswire (USA) | ||
| 02.06. | Tenaya to present gene therapy trial data Wednesday | 1 | Investing.com | ||
| 02.06. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics to Announce New Interim Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 | 1 | GlobeNewswire (USA) | ||
| 29.05. | Tenaya Therapeutics, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 15.05. | Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements | 7 | Benzinga.com | ||
| 15.05. | Tenaya reports interim gene therapy trial results for heart condition | 18 | Investing.com | ||
| 15.05. | Tenaya Therapeutics, Inc.: Positive Interim Data from Cohorts 1 and 2 of Tenaya's RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC | 483 | GlobeNewswire (Europe) | All Patients Achieved Meaningful Decreases (Mean = 64%) in Daily Premature Ventricular Contraction Count TN-401 Gene Therapy was Well Tolerated at 3E13 vg/kg and 6E13 vg/kg Doses Post-dose Biopsies... ► Artikel lesen | |
| 06.05. | Tenaya Therapeutics GAAP EPS of -$0.09, revenue of $0.2M | 11 | Seeking Alpha | ||
| 06.05. | Tenaya Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | Tenaya Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.04. | Tenaya to present TN-401 gene therapy trial data at ASGCT | 13 | Investing.com | ||
| 27.04. | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026 | 3 | GlobeNewswire (USA) |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 94,80 | -2,07 % | Moderna explodiert um 100%, BioNTech um 20%! Was tun? | Moderna explodiert um 100%, BioNTech um 20%! Was tun ► Artikel lesen | |
| VALNEVA | 2,945 | +1,24 % | Valneva: EMA startet Prüfung des Lyme-Borreliose-Impfstoffs | Pfizer und Valneva haben mit ihrem gemeinsam entwickelten Lyme-Borreliose-Impfstoffkandidaten PF-07307405 einen wichtigen regulatorischen Schritt in Europa erreicht. Die Europäische Arzneimittel-Agentur... ► Artikel lesen | |
| AMGEN | 370,50 | -2,22 % | Krebsimpfstoff-Kaufrausch: BioNTech nach +22 % - doch Anleger könnten genau das Falsche gefeiert haben | © Foto: picture alliance / Laci Perenyi | Laci PerenyiEine Analystin von Leerink Partners zieht aus den gefeierten Moderna-Daten eine deutlich skeptischere Schlussfolgerung für BioNTech. Entscheidend... ► Artikel lesen | |
| NOVAVAX | 7,230 | -3,98 % | Recursion, Novavax and Crispr Stocks Trending in Pre-Market-Here's Why | ||
| BIOGEN | 184,84 | -2,57 % | Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month? | ||
| CRISPR THERAPEUTICS | 49,970 | -2,61 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| OCUGEN | 1,196 | -5,38 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,106 | -0,36 % | INOVIO shares jump 18% after Q2 beat | ||
| BIONXT SOLUTIONS | 0,210 | 0,00 % | BioNxt erreicht wichtigen Meilenstein im klinischen Cladribin-Programm mit Abschluss des IMPD vor Beginn der klinischen Studien am Menschen | VANCOUVER, BC / ACCESS Newswire /
19. August 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives
Biowissenschaftsunternehmen, das... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,450 | -4,38 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,700 | -5,98 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| TEMPUS AI | 57,49 | +9,65 % | Tempus AI Aktie im Höhenflug: Analysten-Upgrade und Studienerfolg beflügeln den Kurs | ||
| VIVORYON THERAPEUTICS | 1,125 | +0,45 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,656 | +0,42 % | 'We're not afraid of competition': BioCryst CEO sets out strategy after scrapping internal discovery | ||
| BIOMARIN PHARMACEUTICAL | 58,02 | -2,32 % | BioMarin Pharmaceutical Inc.: BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline | BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones
Alesta to spin out all non-ALE1 assets... ► Artikel lesen |
Das Unternehmen TENAYA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,92 % bei einem Aktienkurs von 0,692 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TENAYA THERAPEUTICS INC finden Sie auf Wallstreet Online.